Psychedelics

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

Atai reports its Q2 2022 results, announces a new $175 million loan facility and streamlines its operations.

TSI EDITOR | 2022-08-15

MindMed Board of Directors Approves Reverse Share Split

Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.

TSI EDITOR | 2022-08-04

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

Compass Pathways reports its Q2 2022 results. Preparing for its Phase 3 clinical trial for TRD. Net loss of $21.0 million. Cash (and equivalents) of $207.2 million.

TSI EDITOR | 2022-08-04

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.

TSI EDITOR | 2022-07-28

Red Light Holland to Acquire Two Wellness Shops in the Netherlands: SmartShop Utrecht and SmartShop OSS

Red Light Holland acquires two of the Netherlands premier shops for psychedelic truffles and wellness products.

TSI EDITOR | 2022-07-26

Pasithea Therapeutics Awarded a Drug Development Research Grant

Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease.

TSI EDITOR | 2022-07-14

Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs

Awakn Life Sciences announces UK government grant funding to cover 2/3rds of the costs of its Phase III clinical trial for alcohol use disorder (AUD).

TSI EDITOR | 2022-07-20

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.

TSI EDITOR | 2022-07-19

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.

TSI EDITOR | 2022-07-06

Red Light Holland and Superstar Wiz Khalifa to Launch Naturally Occurring Psilocybin and Mushrooms Wellness Brand: Mistercap

Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland's MISTERCAP brand of psilocybin-based products.

TSI EDITOR | 2022-06-30